Lactobacillus Strains Inhibit Inflammatory Markers in Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like systemic lupus erythematosus (SLE) have significant side effects and do not effectively address the underlying inflammation and complications such as cardiac and hepatic diseases, with limited understanding of the regulatory mechanisms involved in using Lactobacillus strains for these conditions.
Innovation Solution
An isolated strain of Lactobacillus species, including Lactobacillus paracasei strain GMNL-32, L. reuteri strain GMNL-89, and L. reuteri strain GMNL-263, is used in a medical composition to inhibit inflammatory markers like MMP-9, CRP, IL-1β, TNF-α, IL-6, and iNOS, administered orally to treat and prevent SLE-related cardiac and hepatic complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications are used to treat SLE, then symptoms can be treated, but significant side effects occur
Solution Approach 1:
The patent introduces Lactobacillus strains as intermediary organisms that mediate the treatment of SLE. These probiotic bacteria act as a biological mediator that modulates the immune system to reduce autoimmune responses and inflammation, thereby treating SLE symptoms without the harmful side effects of conventional medications. The Lactobacillus strains serve as a natural bridge between the host immune system and the pathological autoimmune processes.
Solution Approach 2:
The patent converts the harmful overactive immune response that causes SLE into a beneficial therapeutic effect. By administering Lactobacillus strains, the overly active immune system is redirected and modulated to produce anti-inflammatory effects and reduce autoimmune attacks. The same immune system that causes harm through aberrant immunity is transformed into a beneficial force that fights inflammation and protects against tissue damage.
2Ease of operation
If current treatments address SLE symptoms, then symptom relief is achieved, but underlying inflammation and complications are not effectively addressed
Solution Approach 1:
The patent applies preliminary action by addressing the root cause of SLE (underlying inflammation and immune dysregulation) before symptoms fully manifest or worsen. The Lactobacillus strains are administered to proactively modulate the immune system and reduce inflammation at its source, preventing the development of complications such as cardiac and hepatic diseases rather than merely treating symptoms after they appear.
Solution Approach 2:
The Lactobacillus strains perform multiple functions simultaneously: they modulate the immune system to reduce autoimmune responses, inhibit inflammatory markers, protect against tissue damage, and prevent complications in multiple organ systems. This multi-functional approach addresses both symptom relief and underlying pathophysiology, as well as preventing cardiac and hepatic complications that conventional single-function treatments cannot address.
3Reliability
If Lactobacillus strains are used to treat SLE, then inflammatory markers are reduced, but regulatory mechanisms are not fully understood
Solution Approach 1:
The patent employs feedback mechanisms where the Lactobacillus strains interact with the host immune system, and the immune system's response to these bacteria provides feedback that further modulates inflammatory pathways. The bacteria produce metabolites and signaling molecules that regulate immune cell activity, creating a feedback loop that maintains anti-inflammatory effects. This self-regulating system continues to inhibit inflammatory markers like MMP-9, CRP, IL-1β, TNF-α, IL-6, and iNOS through ongoing immune-bacteria interactions.
Data Source
AI summary
The present invention is related to a Lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of Lactobacillus paracasei strain GMNL-32, L. reuteri strain GMNL-89 or L. reuteri strain GMNL-263, and a pharmaceutical carrier, for treating syndromes and related complications of the autoimmune diseases.